ibrutinib — CareFirst (Caremark)
High-grade B-cell lymphoma (including double/triple hit lymphoma and not otherwise specified)
Initial criteria
- Imbruvica used as a single agent subsequent treatment in members who are non-candidates for transplant
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on Imbruvica
Approval duration
12 months